Replies to post #379205 on Anavex Life Sciences Corp (AVXL)

[growingpain]

The change is a way to almost directly compare to the lecanamab results

The change allows them to do a one-sided t-test which produces half the p-value of the usual two-sided test, so if they follow this approach, they are more likely to meet the endpoints. However, a one-sided test is almost never used in practice so I have doubts about whether FDA or any other agency would accept that.

With regard to Lecanemab, I had the impression that the original endpoints were more aligned with the Lecanemab trial.